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OBJECTIVES: To provide evidence to assist decision making and cost-effective in-
vestment in population-based public health interventions designed to prevent obe-
sity and obesity-related health problems in New Zealand. The findings will inform
policy makers about the relative merits of different investments, with a view to
reducing the prevalence of a range of chronic health problems. METHODS: Follow-
ing a systematic review of literature, a cost-utility analysis was conducted using a
lifetime model to rank the cost-effectiveness of selected intervention scenarios in
the New Zealand setting. In all, 1- scenarios across six interventions were consid-
ered; six interventions considered the whole New Zealand population, two of
which considered separate estimates of the cost-effectiveness relevant to the
Mâori and the Pacific populations individually. For each intervention, a simulation
model estimated the increase in BMI for individuals exposed to the intervention
and for those not exposed. The model then calculated the likelihood of individuals
in each group contracting any of fourteen BMI-related chronic illnesses, and the
consequential survival and quality of life. From this, the quality adjusted years of
life gained from the intervention were estimated. Similarly the additional cost of
the intervention group was estimated by considering the cost of the intervention
itself, and the lifetime costs of healthcare in relation to the fourteen chronic con-
ditions for both the intervention and control groups. Increases in expenditure due
to increased life expectancy were also considered. RESULTS: The ten scenarios
ranged from highly cost-effective to not offering good value. Four of the interven-
tions appeared highly cost-effective at less than NZ$10,000 per QALY gained.
CONCLUSIONS: The most cost-effective interventions for obesity prevention
would appear to be a school-based programme for children and general health
screening and advice for adults in a primary care setting, though all were highly
sensitive to duration of benefit and discounting.
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OBJECTIVES: Hypertension is ranked as the 4th leading cause of morbidity in the
Philippines, and as such, it greatly contributes to the increasing health expendi-
tures of the country. The Philippine Health Insurance Corporation (PhilHealth), the
mandated provider of social health insurance in the country, currently only has an
inpatient benefits package system for hypertension, causing many members and
beneficiaries to avail of this rather than more cost-effective outpatient mainte-
nance treatments. This study explores the possibility of contributing to the formu-
lation of an outpatient benefits package for PhilHealth by probing into the willing-
ness to pay of patients for anti-hypertensive healthcare. METHODS: An Ordinary
Least Squares regression model with a log-transformed outcome variable to mea-
sure WTP was specified using various socio-economic, demographic, and health
status data from PhilHealth Member Surveys. A contingent valuation approach was
elicited to measure the level of WTP among respondents. An asset valuation
method also complements the WTP analysis to assess ability to pay. RESULTS:
Mean WTP was significantly (p 0.01) associated with asset ownership, which was
used as a proxy variable for long-term wealth. The adjusted mean WTP amounted
to $3.3 per month for anti-hypertensive medicines. WTP was also observed to be
significantly higher for non-paying retirees and indigent members, which are the
two most vulnerable groups in the population.CONCLUSIONS:Based on the results
of the study, it is deemed necessary for PhilHealth to enhance safety nets for
vulnerable groups and employ cost-effective measures through an outpatient ben-
efit package for hypertension. WTP analysis, as a preference measure, is a helpful
tool in determining the economic value of medical treatments to PhilHealth ben-
eficiaries and provide basis for costing the rate of premiums for outpatient benefit
packages.
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OBJECTIVES: The number of patients suffering cardiovascular diseases increase
annually worldwide. The main objective of this study was to evaluate the utilisa-
tion of renin- angiotensin system agents (C09), as the group of medicines with
highest consumption in terms of expenditures units, number of packages and DDD
in Slovak Republic within the years 2006 -2010. METHODS: Analysed data were
abstracted from two databases – PharmaData and IMS. Data were studied in accor-
dance with Daily Defined Dosage (DDD), financial units (€) and number of packages
prescribed every year. RESULTS: The consumption of Renin –Angiotensin system
agents increased within the years 2006-2010 as in number of packages as well as in
terms of financial units and DDD. The most prescribed were plain ACE Inhibitors
(C09A) and they raised in number of packages from 3,528,618 (2006) to 483,4360
(2008), and slightly decreased until 2010 (4,409,095). In accordance with financial
expenditures, the highest consumption was in the group Angiotensin II receptor
blockers plain (C09C). The expenses increased sharply from 58,4540€ in 2006 to
1,397,097€ in 2010. The financial expenses on Angiotensin II receptor blockers com-
bined (C09D) raised from 440,299€ (2006) to 107,2043€ (2010). According to DDD the
highest consumption can be seen in C09A – ACEI plain, followed by C09B – ACEI
combined, C09C Angiotensin II receptor blockers plain and the lowest in group
C09D Angiotensin II receptor blockers combined. CONCLUSIONS: This study con-
cluded that ACEI plays an important role in treatment of cardiovascular diseases,
they are preferred, most prescribed and not so expensive as Angiotensin II receptor
blockers.
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OBJECTIVES: Acute coronary syndrome (ACS) treatment guidelines recommend a
range of interventions to prevent recurrence. The objective of this analysis was to
assess patterns of resource use prior to and following hospitalisation for unstable
angina (UA), ST elevation myocardial infarction (STEMI) and non-ST elevation
myocardial infarction (NSTEMI). METHODS: Unique identifiers were used to link
patients in a comprehensive hospital registry (Myocardial Ischaemia National Au-
dit Project), with longitudinal primary care data (General Practice Research Data-
base) and outcomes (Hospital Episode Statistics). The study population comprised
patients 40 years, hospitalised for ACS from 2003-2009, discharged home. Re-
source utilisation was estimated at: 1) 1-2 year(s) prior to the hospitalisation; 2) one
year prior to the hospitalisation to the hospitalisation itself; 3) discharge to one
year after discharge; and 4) 1-2 years after discharge. Prescribed medications, con-
sultations, laboratory tests and referrals to specialist care were assessed from
GPRD. Hospital admissions and days spent in hospital, by cause, were assessed
from HES. Analyses were repeated by discharge diagnosis and for patients pre-
scribed clopidogrel in primary care within three months of discharge. RESULTS:
Utilisation of all primary and secondary care resources assessed increased in the
first three time periods, peaked in the year following discharge, and decreased in
the second year. The average number of medications prescribed (mean (s.d.)) rose
from (1)8.5(6.9) to (2)9.6(7.3) to (3)14.2(6.7), followed by a decrease to (4)12.7(6.5). The
average number of days spent in hospital rose from (1)2.7(11.1) to (2)4.5(12.8) to
(3)8.5(20.3), followed by a decrease to (4)4.4(15.1). Resource utilisation was lower in
patients with STEMI compared to UA and NSTEMI, but no difference in resource use
was observed for patients treated with clopidogrel. CONCLUSIONS: Primary and
secondary care resource utilisation increases prior to an ACS hospitalisation, with
a peak in the year following discharge, and a slight decrease in the second year.
Cardiovascular Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES:Antihypertensive agents have been shown to reduce the risk of major
cardiovascular events. However, there are no large effectiveness studies which
have assessed adherence to antihypertensive medications and major cardiovascu-
lar outcomes in high risk individuals who have recently suffered an ischemic
stroke. Our primary aim was to evaluate the relationship between antihyperten-
sive drug adherence and non-fatal vascular events in a cohort of older patients
hospitalized for an ischemic stroke and discharged in the community. METHODS:
A cohort of 14, 227 patients with an ischemic stroke was reconstructed from indi-
viduals 65 years and older who were treated with antihypertensive agents between
1999 and 2007. A nested case-control design was conducted to evaluate the occur-
rence of non-fatal major cardiovascular outcomes including stroke or myocardial
infarction. Every case was matched by age and duration of follow-up with up to 15
randomly selected controls. The adherence to antihypertensive drugs was mea-
sured with the medication possession ratio. Conditional logistic regression models
were performed to estimate the rate ratio of non-fatal vascular events associated
with adherence to antihypertensive agents, adjusting for various potential
confounders. RESULTS: Mean patient age was 75 years, 54% were male, 23% had
diabetes, 47% dyslipidemia, 38% coronary artery disease, and 14% atrial fibrillation
or flutter. Adherence to antihypertensive therapy of 80% decreased the risk of
non-fatal vascular events RR: 0.74 (0.67-0.83), compared to an adherence of 80%.
A reduction in all cause mortality RR: 0.52 (0.47-0.58) was also associated with
higher adherence. Male gender and cardiovascular disease were also risk factors
for non-fatal vascular events. CONCLUSIONS: Our study suggests that higher ad-
herence to antihypertensive medication is associated with a risk reduction of non-
fatal vascular events and all-cause mortality among patients with a recent isch-
emic stroke.
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EVALUATION OF THE MEASUREMENT PROPERTIES OF THE ANTIHYPERTENSIVE
ADHERENCE SURVEY
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